The quarter cleared the standing bar on both sales and adjusted profit. Adjusted EPS of $4.48 exceeded the published consensus of roughly $4.36, while revenue of $84.8B was modestly above the roughly $84.35B expectation. The beat was supported by a 15-basis-point expansion in adjusted operating margin to 1.46%, not just higher volume. (Quarterly Results; Non-GAAP Reconciliation; Segment Results)
| Metric | Q3 FY2026 actual | Q3 FY2025 | Published expectation / prior outlook |
|---|---|---|---|
| Revenue | $84.8B, +5.1% | $80.7B | ~$84.35B consensus (Quarterly Results) |
| Adjusted diluted EPS | $4.48, +12.0% | $4.00 | ~$4.36 consensus (Non-GAAP Reconciliation) |
| Adjusted operating income | $1.24B, +17.0% | $1.06B | — (Non-GAAP Reconciliation) |
| Adjusted operating margin | 1.46%, +15 bps | 1.31% | — (Segment Results) |
| FY2026 adjusted EPS guidance | $17.75–$17.95 | — | $17.70–$17.90 previously (Fiscal Year 2026 Guidance) |
| Nine-month adjusted free cash flow | $1.14B | — | ~$3.0B full-year target unchanged (Cash Flow; Adjusted Free Cash Flow Reconciliation; Fiscal Year 2026 Guidance) |
The outlook raise is real but narrow, which tempers an otherwise stronger quarter. The adjusted-EPS range moved up by only $0.05 at each end, to a midpoint of $17.85—above the previously published consensus near $17.76. But revenue growth, adjusted operating-income growth, free-cash-flow, capital-spending, and interest-expense targets were left unchanged. Management explicitly ties the update in part to completing $1.0B of repurchases earlier than planned, so this is more of an EPS/share-count upgrade than a broad upgrade to operating assumptions. (Fiscal Year 2026 Guidance; Quarterly Results)
Underlying profitability improved, though the acquisition is doing meaningful work. U.S. Healthcare Solutions revenue grew 4.9%, but segment operating income rose 15.9%; International operating income rose 20.8%. The margin lift reflects OneOncology and higher pharmaceutical sales, while GLP-1 sales remain a mix headwind because they carry lower gross margins. Since OneOncology closed in February, its contribution was already known; the positive surprise is that combined profit conversion still exceeded expectations. (Segment Results — U.S. Healthcare Solutions; Segment Results — International Healthcare Solutions)
The cleaner adjusted result matters more than the GAAP headline. GAAP EPS was $3.94, but it included a larger LIFO inventory credit and an $88.6M litigation/opioid-related credit; adjusted EPS removes those items along with acquisition and restructuring costs. The $4.48 adjusted figure therefore provides the better read on the quarter's operating beat. (GAAP to Non-GAAP Reconciliation)
The trade-off remains a more leveraged post-acquisition balance sheet. Net interest expense rose 72% year over year to $140.7M as debt funded OneOncology, and long-term debt stood at $11.44B at June 30 versus $7.54B at fiscal year-end. Operating cash flow improved sharply year over year, but cash fell to $2.82B after acquisition spending, buybacks, and financing activity. That does not undo the earnings beat, but it limits how much of the stronger profit can be treated as cost-free. (Quarterly Results; Balance Sheet; Cash Flow Statement)
Read the original 8-K on SEC EDGAR ↗